Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 20/20 | 0.45 |
| ▸ | MMP12 | P39900 | 5/20 | 0.45 |
| ▸ | MMP14 | P50281 | 9/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2286337 | 1.00 | MMP13 (0.45) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL2292206 | 0.85 | MMP13 (0.44) | MMP13MMP12MMP14 | |
| SCHEMBL4009583 | 0.85 | MMP13 (0.44) | MMP13MMP12MMP14 | |
| SCHEMBL942669 | 0.82 | MMP13 (0.44) | MMP13MMP12MMP14 | |
| SCHEMBL6835855 | 0.82 | MMP13 (0.44) | MMP13MMP12MMP14 | |
| SCHEMBL4010084 | 0.81 | MMP13 (0.44) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL940852 | 0.81 | MMP13 (0.53) | MMP13MMP12MMP14 | |
| SCHEMBL2289321 | 0.80 | MMP13 (0.43) | MMP13MMP12MMP14 | |
| SCHEMBL5241113 | 0.80 | MMP13 (0.43) | MMP13MMP12MMP14 | |
| SCHEMBL3929411 | 0.80 | MMP13 (0.43) | MMP13MMP12MMP14KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7648992-B2 | Hydantoin derivatives for the treatment of obstructive airway diseases | ASTRAZENECA AB (SE) | 2010-01-19 | — | — | US | disclosed |
| WO-2009007747-A2 | HYDANTOIN DERIVATIVES USED AS MMP12 INHIBITORS | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080064710-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| EP-1778673-A1 | NOVEL HYDANTOIN DERIVATIVES FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006004532-A1 | NOVEL HYDANTOIN DERIVATIVES FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064710-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | HRH4, HRH1, HRH2 | MMP13 519/4885MMP12 1794/4885MMP14 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.